Why we work with pharma
To find a cure fast we need to work in collaboration with all stakeholders, including pharmaceutical and biotechnology companies. We select partners who work in the field of non-Hodgkin Lymphoma, and who often have a particular focus on follicular lymphoma, whose engagement reflects a commitment to understanding the patient perspective and collaborating constructively with patient groups like the FLF.
Our strategy, activities or information will not be influenced by our workings with Pharmaceutical Industry partners/collaborators.
We are grateful to the companies that support our mission and help make these vital programs possible.
Read our policy on working with the pharmaceutical industry here.
Pharma Company & Funding Amount
BeOne – $38,000
- ICML Symposium 2025
Ipsen Biopharmaceuticals, Inc. – $89,400
- FLF Patient Education & Webinar Series 2
- Ipsen Survey
AstraZeneca – $132,000
- ICML Symposium 2025
- FLF Patient Education & Webinar Series 2
Novartis Pharma AG – $59,850
- ICML Symposium 2025
- Global Patient Survey
Genmab/AbbVie– $195,759
- FLF Patient Education & Webinar Series 2
- FLF Community & Insights Initiative
Kite/Gilead – $25,000
- ICML Symposium 2025
Bristol Myers Squibb (BMS) – $45,000
- ASH – Accelerating the Cure program
Incyte – $139,967
- ASH – Accelerating the Cure program
- FLF Patient Education & Webinar Series 2
Plexus – $5,000
- Plexus (Sponsored by Genentech)